Treatment With Mecamylamine in Smoking and Non-smoking Alcohol Dependent Patients

Conditions

Alcoholism

Trial Phase

Trial Purpose and Description

Trial Purpose

The purpose of the study will be to evaluate the efficacy of mecamylamine in reducing alcohol consumption in smoking and non-smoking alcohol dependent patients.

We hypothesize that mecamylamine will result in a greater reduction of alcohol consumption than placebo. We further hypothesize that mecamylamine will be effective in reducing both alcohol consumption and smoking in a subset of alcoholics who also smoke.


Participation Guidelines

Age:
18 Years - 60 Years
Gender:
Both

Eligibility Criteria

Inclusion Criteria:

  • Individuals with DSM-IV diagnosis of alcohol dependence
  • Smokers and non-smokers
  • Patients who do not require psychotropic medication for the management of their
    psychiatric symptoms
  • Individuals with a history of substance dependence (other than alcohol and tobacco)
    but have not met criteria for substance dependence in the past 30 days
  • Women with acceptable method of contraception

Exclusion Criteria:

  • Pregnant women
  • Medications thought to influence drinking behavior including: acamprosate,
    disulfiram, naltrexone and ondansetron
  • Underlying medical conditions
  • History of glaucoma, prostatic hypertrophy, urethral obstruction, cerebral
    arteriosclerosis, pyloric stenosis, or a history of hypersensitivity to mecamylamine
  • DSM-IV diagnosis of bipolar disorder, schizophrenia, and schizophrenia-type disorders
  • Unstable medical conditions
  • Patients who require psychotropic medication for the management of an active
    psychiatric disorder
  • Patients on pharmacological treatment for alcohol and/or nicotine dependence
Sponsor:
Elizabeth Ralevski
National Institute on Alcohol Abuse and Alcoholism
Dates:
02/12/2004
Last Updated:
Study HIC#:
0402026364